Currently used non-specific immunosuppressive drugs often require intervention in myasthenia gravis (MG) and clinical improvement varies widely. To analyze the therapeutic effect of mycophenolate mofetil (MMF) in experimental autoimmune MG (EAMG), rats were immunized with acetylcholine receptors (AChRs) and subsequently treated with MMF or vehicle. MMF treatment resulted in a significant suppression of anti-rat AChR antibody titers. Interestingly, no abnormalities of neuromuscular transmission and adverse side effects were detected in MMF-treated EAMG animals. Moreover, anti-rat AChR antibody titers correlated to an improvement of clinical outcome. In conclusion, our data suggest that MMF acts as a potent immunosuppressant drug in EAMG.
Introduction
Myasthenia gravis (MG) is a potentially life-threatening but treatable organ specific autoimmune disorder, characterized by weakness and fatigability of voluntary muscles, i.e. ocular, bulbar, limb and respiratory muscles. In about 85% of patients (Lindstrom et al., 1976) , auto-antibodies against the nicotinic acetylcholine receptor (AChR) in the postsynaptic membrane of the neuromuscular junction are responsible for these symptoms, and have been shown to destroy neuromuscular transmission by different mechanisms: cross-linking of AChRs leading to increased AChR turnover, functional blockade of the acetylcholine-binding sites, complement-mediated damage to the postsynaptic membrane (Drachman, 1994) , and destruction of proteins involved in neuromuscular formation (MartinezMartinez et al., 2007) . Moreover, auto-antibodies that bind to the muscle specific protein kinase (MuSK), are present in a subgroup of patients with MG who do not have antibodies against the AChR (Hoch et al., 2001) .
Currently many therapies are available for MG patients, all intervening with different targets of the disease. Thymectomy is nowadays a widely accepted and practiced form of treatment for MG and is performed in an attempt to induce complete remission or to reduce long-term need for immunosuppression (Gronseth and Barohn, 2000) . In contrast, anti-cholinesterase agents are frequently used in the early disease course to decrease MG symptoms as they inhibit acetylcholine esterase from hydrolyzing acetylcholine. The prolonged exposure time of acetylcholine to AChRs in turn leads to improved neuromuscular transmission and muscle strength, however without affecting the autoimmune attack itself (Richman and Agius, 2003) . Intravenous immunoglobulin (Gajdos et al., 2006) and plasmapheresis (Gajdos et al., 2006; Lehmann et al., 2006) are mostly temporary treatments used to produce rapid improvement during myasthenic crises or acute exacerbations. Finally, long-term immunosuppressives like corticosteroids, azathioprine, cyclosporine A, tacrolimus,
